Coherus Oncology, Inc. (CHRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.42+3.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CHRS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Grow sales of LOQTORZI in recurrent/metastatic nasopharyngeal carcinoma and expand patient starts and therapy duration.
Stated as a priority in 2 of last 2 quarters. LOQTORZI net revenue grew from $11.8 million in 2026-Q1 to $13.6 million in 2026-Q2 (+15%), and from $10.0 million in 2025-Q2 to $13.6 million in 2026-Q2 (+37%). Management emphasizes growth via new patient starts and therapy duration, and the trajectory is delivering.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“LOQTORZI net revenue of $13.6 million in Q2 2026, a 37% increase over $10.0 million in Q2 2025, and a 15% increase versus $11.8 million in Q1 2026.”
“LOQTORZI revenue for Q1 2026 was $11.8 million, a 61% increase over $7.3 million in Q1 2025.”
Progress clinical trials of tagmokitug and casdozokitug with multiple data readouts expected in second half of 2026.
Stated as a priority in 2 of last 2 quarters. Management reports ongoing clinical trials for tagmokitug and casdozokitug with multiple data readouts expected in 2H 2026. While no financial metrics directly quantify progress, the recurring focus and trial enrollment completion indicate steady advancement.
“Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer; data readouts expected in 2H 2026.”
“Tagmokitug development expands with pharmacological and clinical program differentiation; casdozokitug Phase 2 trial enrollment complete with data readout expected mid-2026.”
Control operating losses through cost reductions including lower headcount, infrastructure, and clinical trial expenses.
Stated as a priority in 2 of last 2 quarters. R&D expenses decreased from $26.3 million in 2025-Q2 to $21.4 million in 2026-Q2; SG&A expenses decreased from $26.0 million to $21.0 million; net loss from continuing operations improved from $44.9 million to $33.3 million. Management is delivering on cost control and loss reduction.
“R&D expenses were $21.4 million and SG&A expenses were $21.0 million in Q2 2026, down from $26.3 million and $26.0 million in Q2 2025 respectively.”
“R&D expenses were $21.5 million and SG&A expenses were $23.1 million in Q1 2026, down from $24.4 million and $26.0 million in Q1 2025 respectively.”
Raise capital through equity offerings to fund operations and support pipeline development.
Newly stated in 2026-Q1. Management executed a public equity offering raising $53.6 million net proceeds to support operations. This is a one-time capital raise with no subsequent equity financing stated in later quarters.
“During Q1 2026, Coherus sold 32,890,000 shares in a public offering for net proceeds of $53.6 million.”
Divest remaining biosimilar assets via CVR special dividend to focus on innovative oncology pipeline.
Newly stated in 2026-08-17 press release. Management announced a special dividend of contingent value rights to monetize legacy biosimilar assets and complete transformation into a focused innovative oncology company. This is a strategic capital allocation move with no direct financial metrics yet.
Over the trailing year it converted 5.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.